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Circulating  monocytes  and  tissue  macrophages  (Me) 1 secrete  complement 
proteins and  have  distinct  receptors for  some of these  secreted products.  Al- 
though  hepatocytes  and  possibly epithelial  cells  are  major  sources  of plasma 
complement (1), Mcl synthesize C1 subcomponents (2, 3), C4 (4, 5), C2 (5-7) C5 
(8), C3 (2, 8) and all the components of the alternative pathway and its control 
proteins  (8).  Current  evidence  indicates  that  M~  bear  at  least  two  distinct 
receptors  for  fragments  of activated  C3  (9,  10).  The  type  one  complement 
receptor,  CR1  (205 kD) displays specificity for activated C3 (C3b) (11) and C4 
(C4b) (12). CR 1 interacts with iC3b, the product of C3b cleavage by factor I (9), 
although anti-CR 1 antibodies that block C3b-dependent rosetting do not block 
iC3b-dependent rosetting (13,  14). The type three complement receptor, CR3, 
(170 and 95 kD) interacts with iC3b, and possibly with the further degradation 
product C3dg (9). 
In order to investigate the physiological role of M¢ complement products we 
made use of monoclonal antibodies (ab) that are specific for CR1  (13) and that 
recognize epitopes associated with  CR3 (15,  16).  We found that  deposition of 
M~-derived C3 on the acceptor surface of zymosan particles mediated binding 
and ingestion of zymosan via M~ CR3. Zymosan uptake could also be mediated 
via mannosyl, fucosyl receptors (MFR,  17) in those M~ populations that possess 
both CR3 and  MFR activity (18). These studies indicate a role for M~ comple- 
ment in local opsonization and host defense. 
Materials and Methods 
Animals 
Swiss outbred (PO) and CBAT6T6 and C57bl mice were bred at the Sir William Dunn 
School of Pathology, Oxford, and both sexes used at 20-30 g. 
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1  Abbreviations used in this paper."  ab, antibody; BCG, bacillus Calmette-Gu~rin; C3, third comple- 
ment component; CR1, type 1 complement receptor; CR3, type 3 complement receptor; iC3b, C3b 
cleaved by factor I; FBS, fetal bovine  serum; IM, Iscove's  medium; MFR, mannosyl, fucosyl  receptor; 
Me, macrophages; Oi, superoxide anion; PBS, phosphate-buffered saline; PMA, phorbol myristate 
acetate; SDS-PAGE, sodium dodecyl  sulfate-polyacrylamide  gel electrophoresis; TPM, thioglycollate- 
elicited mouse peritoneal Me. 
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Media and Reagents 
Iscove's modification of Dulbecco's medium  (IM)  was  obtained  from Gibco-Biocult 
Ltd., Paisley, Scotland. Fetal bovine serum (FBS) from the same source was routinely heat 
inactivated (56°C for 30 min) before use.  100 #g/ml kanamycin, 50 #g/ml streptomycin, 
and 50 #g/ml penicillin  were added to media. Phosphate-buffered saline  A and B were 
obtained from Oxoid Ltd., Basingstoke, England. Thioglycollate broth was bought from 
Difco Laboratories, Detroit,  MI. Bacillus  Calmette-Gu6rin (BCG) Trudeau Strain  1011 
was obtained from the Trudeau Institute, Saranac Lake, NY.  Ficoll-Paque was obtained 
from Pharmacia  Fine  Chemicals,  Uppsala,  Sweden.  Mannan,  ribonuclease B', zymosan 
type  A,  cytochrome c,  superoxide  dismutase,  phorbol  myristate  acetate  (PMA),  and 
proteins used as molecular weight standards in SDS-PAGE were all obtained from Sigma 
Chemical Co., St.  Louis,  Me.  Carboxylated latex  beads,  diameter 0.86 tsm, 0.25 meq 
CO~/g (Dew Diagnostic, Indianapolis, IN) were labeled with [3H]tyramine in the presence 
of toluene sulfate (19).  Cycloheximide was purchased from Calbiochem-Behring Corp., 
La Jolla, CA. 
Antibodies 
The rat anti-mouse hybridoma MI/70 (anti-Mac I) and the ab used as tissue  culture 
supernatant were gifts of Dr.  T. Springer, Harvard Medical  School, Boston, MA. This 
defines the CR3 on mouse Me, polymorphonuclear leukocytes (PMN), and NK cells (20). 
MOI, a mouse anti-human ab, a gift from Dr. R. Todd, Harvard Medical School, Boston, 
MA inhibits binding and uptake of iC3b ligands and was used as an ascites (16). F4/80, a 
rat anti-mouse ab specific  for mature  mouse Me  (21)  and  3C10, a  mouse anti-human 
monocyte ab, a gift from Dr. W. Van Voorhis, The Rockefeller University, NY were both 
used as  concentrated hybridoma supernatants  (22).  WMI, a  mouse ab that defines an 
antigenic determinant on the human C3c fragment was used as an ascites  (23).  TO5, a 
mouse anti-human CR1 ab (13) was a gift of Dr. David Mason, Oxford, and was used as 
a tissue  culture supernatant.  All ab were used at saturating concentrations in all experi- 
ments. 
Cells 
Mouse macrophages.  Thioglycollate-elicited  Me  (TPM)  were  obtained  4-5  d  after 
intraperitoneal injection of thioglycollate broth. BCG-activated peritoneal Me (BCG-PM) 
were  harvested  7-14  d  after  intraperitoneai  infection with  ~1  ×  l0  T live  organisms. 
Peritoneal cells were washed and resuspended in either IM or IM 4- 5% FBS and plated 
in 24-well  tissue  culture trays or on glass coverslips  at 8 X 105 or 2 X 105 Me per well, 
respectively. Adherent monolayers were prepared after 2-4 h incubation at 37°C in 5% 
CO2 by washing twice with phosphate-buffered saline (PBS). J774, a murine Me cell line, 
was maintained in spinner bottles at 37°C. Cells were obtained from T75 tissue  culture 
flasks by vigorous agitation, and adhered for 2-4 h in 24-well tissue culture flasks before 
use. 
Isolation of human monocytes.  "Bully coat" from 150 ml of freshly drawn human blood 
from laboratory personnel or from the John Radcliffe Hospital Blood Transfusion Service 
was diluted twofold with IM and mononuclear cells isolated by centrifugation on Ficoll- 
Paque.  The  mononuclear fraction  was  washed  five times  in  IM  at  200 g  to  remove 
platelets.  Cells were resuspended in serum-free IM and cultivated in 24-well tissue culture 
trays at 37°C in 5% CO~ for 45-60 min. An adherent monolayer was obtained by washing 
twice with PBS. 
Culture of  human monocytes.  Purified monocytes were cultivated in 24-well tissue culture 
trays in IM +  20% heat-inactivated autologous serum at 37°C in 5% CO~ for 7 d before 
assay.  During this time cells became well spread and resembled mature Me morphologi- 
cally. 
Ligands.  A  glycoconjugate of mannose-bovine serum  albumin  (MBSA)  with  33-37 
tool of sugar/mol protein was a gift from Dr. P. Stahl, Washington University, St. Louis, 
MO. This material was trace labeled with ~*sI and used at 8 x  l0  s cpm/ng. Zymosan was 246  OPSONIZATION  BY  MACROPHAGE  COMPLEMENT 
boiled for 15 min in 5 mi PBS and pelleted by centrifugation. Zymosan was iodinated by 
a  modification of the chloramine T  method of Greenwood et al.  (24) as described by 
Badwey et al. (25).  Briefly, 250 mg of zymosan was resuspended in 5 ml PBS and 150 ~1 
of 1 mg/ml chloramine T  added with 1.5 mCi of Nal~5I (Amersham, U.K.) at 4°C for 20 
rain. The reaction was terminated by the addition of 200 ~g of potassium metabisulfite. 
The zymosan was washed five times with PBS, resuspended in 20 ml PBS, and dialyzed 
overnight against  500  ml of PBS containing  10  mM  sodium iodide.  After dialysis the 
zymosan was pelleted, washed, and stored in PBS at -20°C. ~8 ×  l0 T zymosan particles 
in 10 #1 (4,000 cpm/#l) were added, routinely, to each assay well. 
Assays 
Uptake and binding of ~51-zymosan.  Mouse M0 or human monocytes were preincubated 
with or without saturating amounts of anti CR3 ab or 1 mg/ml yeast mannan in IM for 
15 min at 37°C in 5% COs. After a further  10 min incubation with 12~I-zymosan (~I00 
zymosan particles/cell),  the  cells were  washed  five times to remove free zymosan. To 
determine total binding and ingestion, cells were solubilized in  1 M NaOH and the cell- 
associated radioactivity measured in a Packard gamma spectrometer (Packard Instrument 
Co., Inc., Downers Grove, IL). Ingestion was assayed as follows. Attached zymosan was 
removed by 15 min treatment with 2.5% wt/vol trypsin solution (Gibco-Biocult Ltd.) at 
37°C and confirmed by phase contrast microscopy and staining with trypan blue. Extra- 
cellular zymosan takes up trypan blue, unlike ingested particles, thus providing a sensitive 
method to detect residual surface zymosan. Routinely, ab were washed out before addition 
of l~5I-zymosan and the assay medium did not contain FBS.  However, some assays were 
performed in the continuous presence of anti-CR3 ab and 5% HI FBS with no difference. 
Mannan was present continuously in all experiments. Degradation of '~SI-zymosan could 
be detected after 60 min incubation with cells at 37 °C by the appearance of trichloracetic 
acid-soluble radioactivity in the medium. Control cultures without cells did not release 
any acid-soluble radioactivity. Results were expressed as cpm/t~g cell protein, detected by 
the Lowry method (26), and as a percentage inhibition of uptake or of total cell-associated 
~25I-zymosan. Nonspeci.fic  binding and uptake were determined by assaying L929 fibro- 
blasts, which lack mannosyl/fucose and complement receptors, (R. A. B. Ezekowitz and J. 
Cardosa, unpublished),  under conditions  similar to Me monolayers. These cells bound 
10-20% of leSI-zymosan when compared with matched Me populations. 
Mannose-spec~c endocytosis.  Uptake was measured using saturating amounts of trace- 
labeled mannose-BSA as described (27), and was inhibited by mannose-rich yeast mannan 
(1  mg./ml) or ribonuclease  B  (1  mg/ml).  Results  were expressed as  ng ligand/•g  cell 
protein. 
Antigens.  Binding of MI/70 to M0 that had been fixed for 10 rain in 0.25% wt/vol 
glutaraldehyde was detected as described (18). Binding of MOI to human monocytes was 
detected by using a  radioiodinated  F(ab')~ rabbit anti-mouse ab, a  gift from Dr.  A.  F. 
Williams, University of Oxford. Both first and second stage ab were used at saturation 
and the number of sites per cell determined (28). 
Single cell analysis.  Coverslip preparations of 2-4 h adherent M# were incubated with 
100 unlabeled zymosan particles/cell with or without anti-CR3 ab and/or yeast mannan, 
1 mg/ml in IM. Preparations were washed five times, treated with 2.5% wt/vol trypsin 
for 15 min at 37°C to remove attached zymosan, fixed in 0.25% wt/vol glutaraldehyde, 
and  ingestion-scored  under  phase  contrast  microscopy.  300  cells  were  examined  in 
duplicate preparations. 
Preparation of C3b-zymosan and iC3b-zymosan.  C3b-zymosan was prepared by incubating 
fresh  PO  mouse serum with  20  mg of boiled zymosan for 20  min at  37°C.  This was 
incubated  with  0.5%  wt/vol sodium  dodecyl sulphate  (SDS)  at  37°C  for  15  rain  and 
washed  five times  in  PBS  to  remove adsorbed  serum  protein  (29).  To prepare  iC3b 
zymosan the C3b zymosan was incubated with isolated Factor I from human plasma and 
purified factor H  in  10 mmol KPOT-, pH 7.4,  for 30 min at 37°C.  The ligands were 
eluted by further incubation with  1 M  hydroxylamine, pH 9.0, and 0.5%  wt/vol SDS 
(29),  which removed C3b and iC3b as determined by 9%  SDS-polyacrylamide slab gel EZEKOWITZ  ET  AL.  247 
electrophoresis (results not shown). Mouse iC3b resembled human iC3b (30).  Binding of 
anti-CR3 ab to these ligands and untreated boiled zymosan was tested by indirect binding 
assay. 
Isolation of C3.  C3 was isolated from human plasma and, where indicated, converted 
to C3b or labeled with  125I tO a specific activity of 1.0-1.8  X  106 cpm/gg as described 
(31, 32).  Factors I and H were isolated as indicated (33). 
Pur~cation  of C3 from  culture supernatants.  Human  monocytes were  incubated  with 
[~S]methionine (Amersham, U.K.), 750 gCi/5 ml methionine-free MEM, supplemented 
with  1% dialyzed FBS,  for 4  h.  Unlabeled human C3 (50 #g) was added as carrier and 
supernatants (0.5-10.0  ml) were precleared by incubation (1.5 h, 4°C) with  1.0-5.0 ml 
(packed volume) of nonspecific rabbit IgG bound to Sepharose 4B (Sepharose-IgG) in 250 
mM NaCI-20 mM EDTA-0.5 mM methionine, pH 7.4.  Culture supernatants were then 
incubated  (12  h, 4°C) with  1.0-5.0  ml (packed volume) of rabbit-IgG anti-human  C3 
bound to Sepharose 4B (Sepharose-anti-C3). The Sepharose-anti-C3 had a binding capacity 
of 120 gg C3/ml packed Sepharose. Sepharose-anti-C3 and Sepharose-IgG were subse- 
quently washed six  times with  2  vol of the buffer noted above.  Non-covalently-bound 
protein was removed by incubation (30 min, 4°C) in 4 vol of 0.1  M glycine-HCl, pH 2.2. 
Eluted material was lyophilized and examined by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) followed by autoradiography (34, 35). 
To investigate whether C3 in culture supernatants is in the native (active) form, the 
C3, still bound to Sepharose-anti-C3, was resuspended in water at pH 9.0, and incubated 
at 100°C for 15 min to induce autolytic cleavage of native C3 (32). C3 was then eluted as 
above and examined by SDS-PAGE and autoradiography. 
Detection of C3 convertase components in monocyte supernatants.  Culture supernatants (300 
#1  of 50-fold  concentrated  material)  from  human  monocytes  cultured  in  serum-free 
medium  were  incubated at  37°C  with  l~SI-labeled  C3  (30 #l;  18  #g) and  300  #1  of a 
suspension of zymosan (10 mg/ml in  2.5  mM sodium veronal-0.15 mM CaCl~-0.5  mM 
MGC12-72.5 mM  NaC1-2.5%  wt/vol  D-glucose-0.1%  wt/vol  gelatin  (DGVB  ÷+ buffer)). 
Portions were withdrawn at intervals (0-60 rain) and the zymosan washed exhaustively 
with DGVB  ++, water,  1 M NaC1, and 0.1% wt/vol SDS.  The t25I radioactivity associated 
with zymosan was determined and the rate of deposition of activated l~5I-labeled  C3 onto 
zymosan was calculated.  Dilutions  of fresh normal human serum were used as positive 
controls. This assay is mainly a measure of factor B + D activity, although classical pathway 
involvement is not specifically excluded. 
Detection oJfilctor I plus cofactor activity in monocyte supernatants.  The rate of breakdown 
of lzSI-labeled C3b to the defined product iC3b in the presence of serum-free monocyte 
culture supernatants concentrated 50-fold was determined by SDS-PAGE and autoradiog- 
raphy (30,  33).  This assay measures factor I plus factor I-cofactor activity. Mixtures of 
isolated factors H  +  1 were used as positive controls. 
Assay for  alternative pathway activation in  human serum.  The  capacity of mannan  to 
activate the alternative pathway was measured as described by Riches and Stanworth (36). 
Inhibition of covalent binding of C3.  The covalent binding of activated C3 was inhibited 
by the use of sodium salicyl hydroxamate as described by Sim et al. (31). 
Detection of Me C3 on zymosan under assay conditions.  Direct evidence that M~-secreted 
C3  was  trapped  on  zymosan under  assay conditions  was  obtained  by preincubating  a 
monocyte monolayer, 5 ×  107 cells/35-mm tissue culture dish, with an inhibitor cocktail 
of MOI, mannan, and TO 5 for 10 min at 37°C to prevent zymosan uptake. Unlabeled 
zymosan,  100  particles/cell,  was  then  added  for  I0  min  and  collected,  pelleted  in  a 
microfuge and bound C3 detected by indirect binding assay using WMI as first-stage ab 
and radiolabeled rabbit anti-mouse second stage ab. The number of C3 molecules bound 
per zymosan particle was calculated by the method described by Mason and Williams (28). 
Superoxide assay.  Superoxide anion  was assayed after addition  of 10  #g of zymosan 
(37).  Macrophage monolayers were preincubated with MI/70 and/or ribonuclease B,  1 
mg/ml before addition of 10/~g of zymosan or 20 ng of PMA. Results were expressed as 
072 released/rag cell protein/15  min. Superoxide dismutase,  25 ug/ml inhibited >80% 248  OPSONIZATION  BY  MACROPHAGE COMPLEMENT 
of cytochrome c reduction. Zymosan in the reaction mixture was routinely removed by 
pelleting in a microfuge for 90 s. 
Results 
Role of CR3 and MFR in Binding and Uptake of l~5I-Zymosan by Human 
Monocytes and Macrophages 
To examine the role of specific cellular receptors in binding of unopsonized 
zymosan,  human  blood  monocytes  (1  h)  and  culture-derived  Me  (7  d)  were 
incubated with  ~5I-zymosan in the presence or absence of MO1  and  mannan, 
inhibitors  of  CR3  and  MFR  activity,  respectively.  Receptor  expression  was 
measured by specific uptake of ~25I-mannose BSA and indirect binding assay of 
MO1  antigens.  Table  I  shows  that  freshly  isolated  human  monocytes  bind 
zymosan mainly by the CR3.  These cells express the CR3 antigen MO1  (1.8  × 
105 2nd stage ab bound per cell) and preincubation with MO 1 inhibited binding 
and  uptake of radiolabeled  zymosan by 78%.  Lack of inhibition by mannan  is 
consistent with the low levels of MFR activity expressed by this population (Table 
I; T.  Mokoena and S.  Gordon,  unpublished).  Most of the monocyte-associated 
zymosan was bound, rather than ingested. 85% of 125I-zymosan could be removed 
from the monocyte surface by trypsin treatment; single cell analysis, not shown, 
revealed that although almost all 1 h adherent monocytes bound zymosan, <80% 
ingested particles. Where ingestion occurred, only one to two particles/cell were 
taken up.  This result is consistent with observations that freshly isolated human 
monocytes bind rather than  ingest opsonized sheep erythrocytes via both C3b 
and iC3b receptors (14). 
TABLE  1 
Effect of  MO1 Antibody and Yeast  Mannan on Binding and Uptake of 12~l-Zymosan by Human 
Monocytes and Macrophages 
Cells 
Cell associated 
l~5I-zymosan 
(cpm/#g cell 
protein) 
Percent inhibition of 
total binding and uptake 
after treatment with: 
Total  Ingestion  MO1  Mannan 
Receptors 
MO1 
Antigens  MFR 
MO1 +  (molecules (nguptake 1251- 
2nd stage  mannose  BSA/ 
mannan  MAb X 105/ ug protein/20 
monocyte  min at 37°C) 
plated) 
Human monocytes 
1 h  42  6  78  4  80  1.8  0.06 
7 d  96  58  43  40  71  2.4  2.40 
Human monocytes were adhered for 1 h or cultivated for 7 d in 24-well tissue culture trays before 
assay of zymosan uptake and receptor expression. Monolayers were incubated in the presence or 
absence of inhibitors for 15 min before addition of 1251-zymosan  for 10 min at 37°C. The total cell- 
associated zymosan represents binding and ingestion; ingestion was determined after 15 rain treat- 
ment with trypsin. Results show one experiment done in triplicate, SD <10%, representative of five 
independent experiments. Cell protein was 40 ± 10 ~g (1 h), 68 ± 6 ug (7 d). EZEKOWITZ  ET  AL.  249 
In contrast,  human  M~ obtained after 7  d  cultivation in  autologous serum 
expressed MFR and CR3  activity and both receptors mediated uptake of 12sI- 
zymosan. (Table I; T.  Mokoena and S. Gordon, unpublished). Total uptake of 
~25I-zymosan by these M#  was greater than by monocytes. MO1  and mannan 
now inhibited uptake to a similar extent, 40% each, and this effect was additive, 
71%. In the absence of inhibitors more than half of zymosan bound by 7 d  Mcl 
was ingested and single cell analysis after trypsin treatment (not shown) indicated 
relatively uniform ingestion, up to three or more particles/cell, after treatment 
with MO 1 or mannan. 
Control experiments established that MO 1 did not bind directly to zymosan, 
unopsonized or coated with C3b or iC3b. Binding of 125I-zymosan to monocytes 
was not inhibited (<20%) by an anti-CR 1 monoclonal ab TO 5 or by an unrelated 
anti-monocyte ab,  3C10.  We concluded that the CR3 mediated recognition of 
zymosan,  either alone,  as  in  monocytes that  express  no  MFR  activity,  or  in 
combination  with  MFR,  in  culture-derived M¢.  We  next  examined zymosan 
uptake by other Mci populations that express CR3 and variable levels of MFR. 
Effect of  M1/70 and Mannan on Uptake ofl2~I-Zymosan by Mouse Me 
BCG-activated peritoneal M~ and J774  cells are able to  ingest unopsonized 
zymosan while expressing low or undetectable levels of MFR, respectively (Table 
II).  Both  these  M~ populations  express the CR3  antigen detected by M1/70. 
Thioglycollate-elicited peritoneal  M~,  which ingest zymosan more vigorously, 
express both  CR3  and  MFR  activity.  The  effects of M1/70  and  mannan on 
uptake of 125I-zymosan by these mouse M~ are also shown (Table II). Uptake by 
BCG-PM  and J774  M~  was  inhibited  88  and  90%,  respectively by  M1/70, 
indicating  that  ingestion  of zymosan  was  almost  entirely  via  CR3.  Zymosan 
uptake by TPM was partially inhibited by M 1/70 (49%) and mannan (30%) when 
used separately and these effects were additive (70%).  Similar effects by both 
inhibitors were noted with resident peritoneal Mcl (not shown). 
Fd'rther control experiments were performed to  characterize the effects of 
TABLE  II 
Effects of M1/70 and Mannan on Uptake of 'z51-Zymosan by Mouse Macrophages 
Cells 
Percent inhibition of uptake 
after treatment with:  Receptors 
Ingestion of  Mac-1  MFR 
~SI-zY  m°san  antigens  (ng uptake 
(cpm/#g 
protein)  M1/70  Mannan  M1/70 +  (molecules  l~SI-mannose 
mannan  2nd stage  BSA/#g pro- 
ab ×  tein/20 min 
x  10~/cell)  at 37°C) 
BCG-PM  87  88  8*  90  5.0  0.63 
J774  92  90  4  92  1.6  0.02 
TPM  205  49  30  70  6.1  2.1 
Macrophages were adhered for 2  h  before assay. Cells were preincubated with inhibitors for  15 
min before addition of 125I-zymosan for 10 min at 37°C. Cell protein in ~tg was: BCG, 40 _  8;J774, 
43 _  6; TPM, 58 4- 5, respectively. Attached zymosan was removed by 15 min trypsin treatment. 
Results of 1 experiment representative of 10 independent experiments, SD ~  10%. 
* Inhibition by mannan varied between 5 and 30% depending on experimental conditions (see Table 
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each inhibitor.  MI/70 did not inhibit  uptake of ]25I-zymosan by human  mono- 
cytes, to which the ab binds with less affinity than to murine Me. All assays were 
routinely  performed  in  the  absence  of serum  although  similar  results  were 
obtained  in  the  presence  of  5%  HI  FBS.  Mannan  inhibition  required  the 
continuous presence of the yeast wall product throughout the assay, whereas the 
anti-CR3 ab was usually washed out after  15 min preincubation.  Mannan  itself 
did not significantly activate the alternative pathway in serum.  Mannan  did not 
inhibit binding of M 1/70 nor did M 1/70 influence uptake of I25I-mannose-BSA. 
The  uptake  of 3H-latex  beads,  particles  that  do  not  activate  the  alternative 
pathway, was unaffected by mannan or anti-CR3 ab. M1/70 inhibited uptake of 
preformed  iC3b  125I-zymosan  to  a  greater  extent  than  unopsonized  zymosan 
although inhibition was not >80%. F4/80, a rat anti-mouse M~ ab, did not affect 
zymosan uptake. Assays were routinely performed for 10 min at 37 °C and results 
shown were highly reproducible. 
Kinetics of inhibition 
TPM and BCG-PM were incubated in serum-free medium with  100 zymosan 
particles per cell for varying periods at 37°C, in the presence of M1/70 and/or 
mannan.  Uptake of ]~5I-zymosan was linear for 20 min and was greater for TPM 
(Fig.  1 B and D). Acid-soluble radioactivity did not appear in the supernatant of 
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FIGURE  1.  Kinetics of inhibition of ]2SI-zymosan uptake by BCG-PM (A and B) and TPM (C 
and D). 8 ×  105 M# were preincubated in Linbro wells with M1/70 and/or 1 mg/ml mannan 
and l*SI-zymosan added for varying lengths of time. Cells were then washed and treated with 
trypsin for 15 min to remove noningested zymosan. Uptake as a function of time is shown in 
B and D. Inhibition (A and C) is expressed as a percentage decrease of uptake and show one 
experiment,  SD  <  10%,  representative  of  six  independent  experiments.  (  ),  MI/70; 
(-- -), mannan. EZEKOWITZ  ET  AL.  251 
either cell population before 50 min, so the plateau observed after 20 min was 
not due to degradation. The extent of inhibition by M1/70  varied markedly 
with time,  but  was relatively constant for mannan in  both populations.  With 
BCG-PM (Fig.  1 A) inhibition of zymosan uptake by M1/70 was maximal (70%) 
at 5-10 min and then decreased rapidly by 20-30 min. Mannan inhibited 15% 
of uptake throughout this period, whether used alone or in combination. With 
TPM (Fig.  1C), inhibition by M1/70  was again maximal at  10 min (50%) and 
decreased rapidly thereafter. Inhibition by mannan was stable and was relatively 
greater (60%), as expected for this population. Both inhibitors together inhibited 
a maximum of 80%. These results confirmed the earlier findings that uptake of 
zymosan over short periods was mediated mainly by CR3  in BCG-PM, and by 
both CR3  and MFR in TPM, and that the inhibitors were additive.  However, 
the CR3 contribution was short-lived. 
Single  cell analysis.  To identify the cells that had taken up zymosan and to 
detect any possible heterogeneity, we next examined adherent populations  by 
phase contrast microscopy. Table III shows that M 1/70 reduced the number of 
zymosan particles/cell and the number of cells labeled in all M0 examined. Only 
TPM,  which  ingested  more  particles  per  cell,  showed  a  significant,  partial 
inhibition by mannan, alone or in combination with M1/70.  The results show 
mostly ingestion. Extracellular zymosan could be stained with trypan blue, and 
after trypsin treatment <10% of cells had attached particles. Previous autoradi- 
ographic studies revealed a  similar uniform expression of Mac  1 and MFR by 
primary mouse M0 populations (27). 
Biosynthesis  and  secretion of alternative  pathway  complement  proteins  by  human 
monocytes.  Previous studies have shown that mononuclear phagocytes can syn- 
thesize and secrete all six alternative pathway proteins (8).  It was important to 
demonstrate that  under assay conditions the formation of iC3b-zymosan,  the 
ligand recognized by CR3, was due to M0-derived complement proteins. These 
TABLE  III 
Single Celt Analysis of Effects of M1170 and Mannan on Uptake of Zymosan 
by Mouse Macrophages 
Cells 
Percent M0 labeled after treatment with: 
None  Ml]70  Mannan  M1]70+ 
mannan 
TPM  A  86  54  70  9 
B  15  46  30  90 
BCG PM  A  25  5  28  4 
B  75  80  72  92 
J774  A  25  3  20  2 
B  72  74  79  54 
Macrophages were cultured for 2 h in IM on glass coverslips and incubated with 
MI/70  and/or  mannan  for  15  rain,  washed,  and  ~100  unlabeled  zymosan 
particles/cell added for  10 min at 37°C.  Preparations were washed five times, 
treated with trypsin for 15 rain to remove attached zymosan, then fixed in 0.25% 
glutaraldehyde  and  scored  under  phase contrast  microscopy.  300  ceils  were 
counted in duplicate preparations. A and B represent percent cells with >5 or 
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experiments were done with human monocytes to facilitate detection of specific 
complement components. 
Biosynthesis of C3.  Freshly  isolated  human  monocytes  were  cultured  with 
[~S]methionine in the absence of zymosan and C3 isolated by affinity chroma- 
tography.  Fig.  2  shows that  labeled  C3  was  present  in  monocyte-conditioned 
medium in a native ("active") form. The C3 a  and/3 chains are visible in track A 
(cf. standard track I). Two bands at 76,000 and 43,000 mol wt are also visible 
in track A. These are characteristic of cleavage of inactive C3 (i.e., C3 in which 
the thiolester is hydrolyzed, but the polypeptide chain is intact) by factors H and 
I (30). This cleavage product is shown in standard track 2. In track B, where C3 
has been treated to induce autolytic cleavage, two additional bands, characteristic 
of autolytic cleavage of C3, are visible at  74,000  and 46,000  apparent mol wt 
(cf. standard track 3).  Since autolytic cleavage occurs only with active C3 (32) 
this shows clearly that a  large proportion  of the S~S-labeled  C3  in the culture 
supernatant is active. 
Evidence that new protein synthesis is also required for uptake of zymosan by 
mouse Me via CR3 but not MFR is given in Table IV. Treatment of peritoneal 
M¢ with cycloheximide but no inhibitor reduced the uptake of ~25I-zymosan to 
an extent comparable to inhibition by M 1/70 alone. Addition of cycloheximide 
and M1/70  inhibited to an extent similar to that of M1/70  alone. Addition of 
mannan augmented inhibition  by cycloheximide to a  greater extent in  TPM 
than  in  BCG-PM,  compatible  with  reduced expression  of MFR  by  BCG-PM. 
Decreased uptake of zymosan via CR3 cannot be accounted for by a decrease in 
surface receptor expression, which is unaltered (<20% change) by cycloheximide 
treatment (Table IV). 
Detection of C3 convertase components in monocyte  supernatants.  Serum free mon- 
ocyte culture supernatants were found to stimulate activation and deposition of 
~25I-labeled C3 onto zymosan (Table VA). Rates of deposition observed were 1- 
3%  of the  rate  observed  with  normal  human  serum.  This  demonstrates  the 
FIGURE 2.  Biosynthetic labeling of C3 by human monocytes. Tracks A-C, autoradiographs 
obtained after SDS-PAGE. (A),  material eluted from Sepharose-anti-C3;  (B), material  heat- 
denatured  to  induce  autolytic  cleavage  before  elution  from  Sepharose-anti-C3;  (C),  total 
monocyte culture supernatants.  Standard tracks 1-4 were stained with Coomassie Blue. Track 
1, C3; track 2, inactive C3 partially cleaved by factors H and I; track 3,  ~active" C3 showing 
partial autolytic cleavage; track 4, molecular weight standards,  myosin, C3b, catalase, ovalbu- 
min, and carboxypeptidase A. Although H and I activity is detectable in serum-free monocyte 
culture supernatant,  the cleavage seen here may he attributable to bovine H and I from fetal 
calf serum  which  also act  on  human  C3b  (30).  Additional minor bands  at about  100,000, 
60,000, and 50,000 apparent mol wt are visible in track A, but these are not C3-derived. EZEKOWITZ ET  AL.  253 
TABLE  IV 
Effect of Cycloheximide on Uptake of ~2sI-Zymosan via CR3 and MFR by Mouse Macrophages 
Cells  Treatment 
Uptake [cpm (percent inhibition)] of 
~25I-zymosan 
Control  MI/70  Mannan 
Receptors 
MI/70 Ag  MFR 
(molecules  (rig uptake 
a251.man_  2nd stage  ab ×  nose BSA/ 
105/ce11)  #g protein/20 
min at 37°C) 
BCG-PM  None  2,680  1,240 (54)  1,809 (32)  5.1  0.63 
Cycloheximide  840 (69)  910 (66)  607 (78)  4.3  0.52 
TPM  None  5,009  2,810 (46)  1,892 (62)  6.8  2.2 
Cycloheximide  2,516 (49)  2,340 (52)  1,550 (69)  5.4  2.0 
5 x  l0  s 1 h adherent peritoneal MS were preincubated for 2 h with 10 #g/ml cycloheximide at 37°C 
and maintained in its presence throughout the assay. Some wells were preincubated with inhibitors 
as described in Tables I and II. Results are expressed as cpm or percent inhibition  of control in the 
absence of cycloheximide.  Results shown are one experiment performed in triplicate  (SD <  6%) 
representative of five independent experiments.  Inhibition  by mannan of uptake by BCG-PM varied 
(cf. Table II).  10 t~g/ml cycloheximide had no effect on cell viability (>95%  excluded trypan blue) 
and reduced plasminogen activator secretion  by both TPM and BCG by 80 4- 15%, this effect was 
fully reversible. 
TABLE  V 
Rates of C3 Deposition and C3b Degradation in the Presence of 
Human Monocyte Culture Supernatants 
A. C3 deposition on zymosan 
Rate of C3b deposition 
Sample  pg]min 
Monocyte supernatant  30 _+ 6 
Control with undiluted human serum  1,600 
B. C3b breakdown to iC3b 
Rate of iC3b formation 
Sample  pg]min 
Monocyte supernatant  1.34 4- .56 ×  l0  s 
Control with 400 ng[ml H  3.6 x  10  ~ 
80 ng]ml I 
c3 convertase  components were detected by measuring the rate of C3 
deposition  on zymosan. Factor I  plus cofactor  activity was assessed by 
measuring the rate of iC3b formation from C3b, as described in Materials 
and Methods. The rate of C3b deposition (A) was linear over 15-20 min, 
with a stable background, and the minimum cumulative deposition  de- 
tectable  was ~6 pg/min. For iC3b formation, the minimum detectable 
rate was ~80 pg]min. 
presence of C3  convertase components in the monocyte supernatant. Similarly 
concentrated serum-free monocyte supernatants were shown to degrade soluble 
*uSI-labeled C3b  to  the  defined product  iC3b  (Table VB).  This  indicates the 
presence of factor I  plus a  factor I cofactor, most likely factor H. 
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TABLE VI 
MI/70 Inhibition of Zymosan-triggered Superoxide Release by Mouse Macrophages 
Cells 
Inhibition [nmol O~/mg protein/15 rain (percent 
inhibition)] after treatment 
None  MI/70  Ribonuclease  B 
BCG-PM + PMA (20 ng/ml)  128.8 _.+ 8  151 + 11  (-18%)  106 _+ 6  (19%) 
+ zymosan  76 + 16  36.8 + 10  (61%)  57.6 + 10  (29%) 
TPM  + PMA  90.8 __+ 6  71.0 + 8  (23%)  67.1 + 10  (28%) 
+ zymosan  63.8 _+ 12  35.5 + 4  (51%)  23.6 ± 8  (63%) 
8 x  105 cells were cultivated in IM +  5% FBS for 2 h and washed three times with HBS. Cells 
were preincubated with inhibitors (see legend to Table I and II). Ribonuclease B (1 mg/ml) was 
used to inhibit MFR since it does not scavenge O~', unlike mannan (37). MI/70  was washed out 
before addition of reaction mixture. The percentage inhibition was calculated, as follows 100 - 
(Inhibition-blank)/(Stimulation-blank). Blank values for BCG-PM and TPM were 10 and 8 nmol 
O~/mg cell protein,  respectively. Experiments show mean +  SD of data from duplicates in one 
experiment,  representative of five independent  experiments. The results obtained were 60% of 
values obtained when assay time was 60 min. MI/70 or ribonuclease B did not cause OF release. 
that transfer of MS complement components onto zymosan occurred under the 
conditions of assay, unlabeled zymosan was incubated for 10 min with a  human 
monocyte monolayer in the presence of a cocktail of inhibitors to prevent uptake. 
The zymosan was then removed and the presence of C3 demonstrated by a trace 
indirect binding assay using an anti-C3 ab, WMI (23). Specific binding to zymosan 
incubated in the presence of monocytes was -4.3  ×  103 C3 molecules/zymosan 
particle. This ab did not detect significant amounts of C3 antigen on the surface 
of monocytes prepared as for assays. Further evidence of a role for C3 in zymosan 
uptake was obtained by addition of the nucleophile sodium salicyl hydroxamate 
(1-5  mM),  which inhibited uptake by BCG-PM and J774  M~ 45-60%,  compa- 
rable to that achieved by M 1/70,  without affecting cell viability. The hydroxa- 
mate is a potent inhibitor of the covalent binding reaction of activated C3 (31). 
Role of CR3 in superoxide secretion.  During phagocytosis or upon appropriate 
stimulation of the plasma membrane by surface active agents like phorbol esters, 
immune  complexes,  and  both  opsonized and  unopsonized  zymosan,  activated 
M#  release  substantial  amounts  of OF  and  H202  (37).  Table  VI  shows  that 
although  M1/70  inhibited zymosan-triggered release of O~ by BCG-PM,  PMA 
could still trigger superoxide release. In contrast, inhibition of zymosan-triggered 
superoxide release by TPM was dependent upon both MFR and CR3 activity. 
Discussion 
Zymosan is widely used to stimulate a respiratory burst in phagocytic cells (37) 
and  to  trigger  release  of arachidonate  metaholites  (38)  and  other  secretory 
products (39). Earlier studies showed that zymosan that had not been opsonized 
by incubation with fresh serum retained much of its biological activity and that 
the MFR could mediate uptake of these particles (17, 37).  However, M~ popu- 
lations  that  lack  MFR  activity,  e.g.,  human  monocytes  and  J774  cells  (40), 
nevertheless bind or ingest unopsonized zymosan. The present studies show that 
the uptake of "unopsonized" zymosan by mononuclear phagocytes can be me- 
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that these receptors act independently or in concert. We have demonstrated that 
C3-derived components are present even in the absence of exogenous comple- 
ment and  have shown  that  the  M~ themselves can generate all  the alternative 
pathway components  required  for opsonization.  Our  studies  provide  the  first 
evidence that secretion of complement components by M~ plays a direct role in 
regulating M~ recognition and effector functions. Similar feedback mechanisms 
could link other  M~ secretory and  endocytic pathways, e.g.,  via intermediates 
such as a2-macroglobulin (41, 42). 
Monoclonal ab and other ligands with defined specificity were used to evaluate 
the  role  of distinct  M~  receptors  in  uptake  of zymosan.  The  M~  CR3  was 
implicated  by the  use of two  independent  monoclonal  ab.  M1/70  specifically 
prevents binding to mouse M~ of iC3b-coated but not C3b-coated erythrocytes 
or EIgG (15) and inhibits immune enhancement of flavivirus replication mediated 
by complement, but not IgG (43). MO1 immunoprecipitates the human analogue 
of Mac-1 and also blocks binding of EiC3b rosettes to normal human monocytes 
(16).  We  have  provided  further  evidence  for  selective  action  by  these  ab. 
Antibodies against CR 1 or other monocyte Mcl ag were inactive, the uptake of 
latex was not affected, and L cell fibroblasts, which do not express Mac-l, failed 
to  take  up  zymosan.  Inhibition  by  mannan  was  not  due  to  consumption  of 
complement,  and  mannan  and  ribonuclease  B,  known  inhibitors  of M~  MFR 
activity (44), showed comparable inhibitory effects. 
All  M~  populations  examined,  including  human  and  mouse  cells,  primary 
inflammatory,  and  activated  M~  and  an  M~  line  expressed  Mac-1  or  MO1 
antigens and showed substantial inhibition  of endocytosis, usually 50% by these 
ab. Inhibition of zymosan uptake by mannan  reflected the level of MFR activity 
and varied from undetectable (human monocytes, J774) to 50% (human culture- 
derived M~, TPM); BCG-activated M~ were intermediate.  The contribution  of 
each receptor was characteristic  for each  M~ population  and  varied independ- 
ently  with  cell  type and  conditions  of assay.  Inhibitors  directed  against  each 
receptor were additive  until  a  maximum  level,  normally  no greater  than  80- 
90%, was reached. Although it is conceivable that a third receptor is involved in 
uptake  of zymosan,  our  studies with  another  ab T05  that  has  been  shown  to 
inhibit  C3b-dependent  rosetting  to  B  lymphocytes (13) argue  against  a  major 
role  for  CR1.  Single  cell  analysis  showed that  inhibition  was uniform  within 
populations. Further studies are needed to establish whether dual recognition by 
both CR3 and MFR operates for each cell and each particle. 
Inhibition  by the anti-CR3  ab implies  that  ligands  derived from C3  such as 
iC3b are generated on the surface of the zymosan particles when these are added 
to Met cultures.  Serum was not required to demonstrate  this phenomenon and 
no  adsorbed  C3  could  be  detected  on  the  surface  of freshly  isolated  human 
monocytes.  Direct  evidence  was  obtained  that  M~  themselves  synthesize  and 
secrete  active  C3  under  similar  experimental  conditions,  as  reported  also  by 
others (45). Furthermore, a requirement for ongoing protein synthesis in uptake 
via  CR3,  but  not  MFR,  was demonstrated  with  cycloheximide which  did  not 
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patible with a requirement for continuing complement synthesis/secretion. Zy- 
mosan binds poorly to  Mg at  4°C,  although receptor function might then be 
affected. In  the present report  we showed further that  C3  antigen could be 
detected on zymosan after exposure to human monocytes and that sodium salicyl 
hydroxamate inhibited uptake of zymosan, presumably by inhibiting formation 
ofa C3-zymosan ester bond (29, 31). 
Other complement system activities were detected in serum-free human mon- 
ocyte supernatants. The results which showed that such supernatants stimulated 
deposition of '25I-iabeled C3 onto zymosan can be most simply interpreted by 
assuming that the monocytes synthesize factors B and D, and possibly P, and can 
therefore assemble the alternative pathway C3b Bb(P) convertase on the zymosan 
surface. Whaley (8) has demonstrated the presence of functionally active B,  D, 
and  P  in  short-term  (<1  d) human  monocyte cultures,  although  Cohen  (46) 
suggested that significant secretion of factor B does not occur until monocytes 
have been cultured for >3 d. Specific cleavage of 125I-labeled C3b to iC3b in the 
presence of serum-free monocyte culture supernatant demonstrates the presence 
of factors H and I in the supernatant. Whaley (8) has demonstrated secretion of 
active factor I in short-term monocyte cultures. Factor H activity was not detected 
in  Whaley's study, although secretion of factor H  antigen was demonstrated. 
The  factor  H  assay  used  by  Whaley was  likely to  be  less  sensitive  than  that 
described here. The complement receptor CR!  has the same factor I - cofactor 
activity as H, but has not been reliably detected in soluble form. It is therefore 
unlikely that the cofactor activity in the supernatants could be attributed to CR1 
rather  than  to  H.  All  the  alternative  pathway  components (47)  can  thus  be 
generated simultaneously in serum-free Mg cultures, as demonstrated recently 
by Brade (48). 
In  light of these considerations it is reasonable to conclude that  the locally 
synthesized Mg alternative pathway proteins opsonize zymosan particles which, 
in turn, bind to Me CR3. Several interesting features of this reaction should be 
noted. Kinetic experiments revealed that the process is fully developed within 
5-10  min,  but  transient.  Rapid  decay of CR3  involvement could be  due  to 
complement lability or consumption of complement components by an excess of 
zymosan. Since C3 and other components could be detected in supernatants in 
the absence of zymosan it is likely that complement secretion is constitutive and 
not dependent on a particulate stimulus. Expression of the CR3 antigen Mac-] 
is also constitutive since it appears early during Mg differentiation (S. Hirsch and 
S.  Gordon,  unpublished  observations) and remains at a  relatively stable  level 
during Mg activation unlike several other plasma membrane determinants (27). 
However, function of the CR3 does vary markedly during cell maturity and in 
response to inflammatory (49), immune (50), and pharmacologic stimuli (14). In 
the present studies locally opsonized zymosan could trigger binding, ingestion, 
and/or release of OF via CR3 as well as the MFR. Unpublished experiments with 
freshly isolated  human  blood  monocytes that  lack  mannose-receptor activity 
indicate that the CR3 by itself can mediate these responses. 
Our  studies  indicate  that  complement  components  synthesized  by  M~  at EZEKOWITZ  ET  AL.  257 
extravascular  sites  could  play  an  important  role  in  opsonization  and  lysis  of 
cellular and microbial targets that activate the alternative pathway. In addition, 
complement-derived  complexes,  proteinases,  and  peptides  could  regulate  the 
functions of macrophages themselves, as well as other cells of the immune system 
(51, 52). 
Summary 
We have examined the role of macrophage (Me) plasma membrane receptors 
for the cleaved third complement component (iC3b; CR3) and mannosyl, fucosyl 
terminated glycoproteins (MFR) in uptake of unopsonized zymosan. Monoclonal 
antibodies  against  CR3,  M1/70  (Mac-l)  and  MO1,  each  inhibited  ~50%  of 
uptake of 125I-zymosan  by murine and human  M~, respectively. Yeast mannan 
inhibited 0-50% of zymosan uptake in various M~, in parallel with their expres- 
sion of MFR. We demonstrated that M~ were the source of C3 in our assay and 
that  the activity of other components of the complement system, namely a  C3 
convertase,  factor  I,  and  a  factor  I  cofactor  were  also  present  in  serum-free 
cultures of human monocytes. Macrophage C3 was deposited rapidly, within  10 
min, on the zymosan particles and mediated binding, ingestion, and stimulation 
of superoxide release in BCG-activated and thioglycollate-elicited peritoneal M~ 
via CR3. Local secretion of complement proteins by M~ themselves can therefore 
opsonize pathogens and cells able to activate the alternative pathway and effect 
their destruction. 
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